Dr Ashkan Emadi speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about a study looking at the combination of pegcrisantaspase and venetoclax in acute myeloid leukaemia
He explains that after conducting robust mechanisms of the transcriptome and translatome it was found that the combination of pegcrisantaspase and venetoclax significantly interferes with the initiation of protein translation in those cells.
Dr Emadi explains that when moving the study to the animal model, the combination arm was highly superior.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.